Reuters logo
BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta
September 20, 2017 / 8:22 PM / 3 months ago

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

Sept 20 (Reuters) - Theravance Biopharma Inc

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

* Theravance Biopharma Inc - ‍Single inhaler triple therapy met study primary endpoint​

* Theravance Biopharma Inc - Theravance Biopharma is entitled to receive an 85% economic interest in royalties paid by GSK on worldwide net sales

* Theravance Biopharma Inc - Is not responsible for any costs related to Trelegy Ellipta Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below